Skip to site menu Skip to page content

Daily Newsletter

18 October 2023

Daily Newsletter

18 October 2023

Fairtility’s CHOLE integrates with EMR platforms

This integration claims to advance the digitalisation of IVF clinics, offering a seamless flow of information.

October 17 2023

Israel-based software company Fairtility has integrated its artificial intelligence (AI) decision support system, CHLOE, with electronic medical record (EMR) platforms used in fertility clinics, including vRepro, IDEAS from Mellowood Medical, nAble IVF, and MedITEX.

This integration claims to advance the digitalisation of IVF clinics, offering a seamless flow of information.

The AI platform will serve as a workflow enhancement and decision support tool set for reproductive care practitioners.

This integration with EMRs will allow seamless, automatic data capture and processing within interconnected systems, resulting in a unified data and insights hub for fertility clinics.

According to the vendor, the advantages of this integration include standardised data inputs for informed decision-making, enhanced clinical accuracy, reduced administrative burdens, and improved patient experiences.

Next Fertility Clinics country manager for Spain and Portugal Adriano Carbone said: “I believe the IVF lab of the future needs to be a streamlined source of priceless data combining the latest technologies like Artificial Intelligence and Next Generation Sequencing (genetics), enabling our staff to consistently make the best clinical choices and personalize each treatment.

“This can only be achieved with full integration of the different systems used in the lab and combined with the clinical data and outcomes via the medical EMR.

“The present is that our clinical care teams are already reaping the benefits of this integration with streamlined workflows, reduced administrative time, and minimised note work in the IVF lab, enabling our team to be more effective and serve more patients with greater accuracy and transparency.”

Fairtility uses transparent AI to improve outcomes in reproductive care, offering clinicians complete visibility into crucial clinical and laboratory parameters with CHLOE.

It aims to expand CHLOE's application across the entire reproductive care journey, from infertility assessment to optimising embryo transfer.

AI will become a key driver of medical device innovation

With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close